Mesa Laboratories (MLAB) Q1 2026 earnings summary

Executive summary

• Revenues increased 2.4% year-over-year to $59.5 million, with core organic growth of 0.4%, driven by Sterilization and Disinfection Control and Calibration Solutions, partially offset by declines in Biopharmaceutical Development and Clinical Genomics.

• Net income rose 40% year-over-year to $4.7 million, with diluted EPS of $0.85 compared to $0.62 in the prior year period.

• Operating income declined 45.1% year-over-year to $3.1 million, mainly due to increased operating expenses, FX, and lower gross margin.

• Gross profit margin decreased to 62.0% from 64.0% year-over-year, reflecting higher costs, tariffs, and unfavorable product mix.

• Profitability, as measured by AOI excluding unusual items, was 21.7% of revenues, down from 26.4% last year.

Financial highlights

• Revenues: $59.5 million, up 2.4% year-over-year.

• Net income: $4.7 million, up 40% year-over-year.

• Gross profit: $36.9 million, down slightly year-over-year.

• Operating expenses: $33.9 million, up 7.0% year-over-year, with a 250 bps increase driven by commercial investments and FX.

• Total net leverage ratio stood at 3.16 as of June 30, 2025.

Outlook and guidance

• Management expects continued upward cost pressure from tariffs and inflation, with plans to offset through price increases, supply chain adjustments, and productivity actions.

• $1.5 million in Biopharmaceutical Development revenues delayed to 2Q26 due to tariff negotiations.

• AOI margin expected to improve in 2Q26 with additional revenue.

• Expects U.S. and European Clinical Genomics revenues to grow, while China revenues are projected to decline.

• Anticipates improvement in Biopharmaceutical Development gross margin as product mix normalizes.